Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
M & A Deals Diagnostics

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

  • Analysis

Executive Summary

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

You may also be interested in...



Qiagen Ready To Rival Abbott With Rapid, Portable Antigen COVID-19 Test

The diagnostics company said the test is scheduled for US launch in Q4 2020.

Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer

Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.

Angle Files De Novo Submission For Parsortix System In Breast Cancer

The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.

Table

View full table

Topics

Related Companies

Tags:
M & A Deals Diagnostics
UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By